Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.57 |
| ▸ | PDE4A | P27815 | 4/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3085107 | 0.85 | ADORA2B (0.58) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL8884694 | 0.84 | ADORA2B (0.61) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL7491449 | 0.80 | ADORA2B (0.56) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL7800909 | 0.78 | ADORA2B (0.50) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL2837684 | 0.76 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL447390 | 0.76 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL618977 | 0.76 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL18285098 | 0.76 | ADORA2A (0.55) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL8952223 | 0.76 | ADORA2A (0.55) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL11572222 | 0.75 | ADORA2B (0.59) | ADORA2BADORA2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1251676-C | Phenyl xanthine derivative | GLAXO GROUP LTD (GB) | 2006-04-19 | — | — | CN | disclosed |
| US-6770267-B2 | Methods of treating periodontal disease | SMITHKLINE BEECHAM CORPORATION | 2004-08-03 | — | — | US | disclosed |
| CN-1515571-A | Phenyl xanthine derivative | — | 2004-07-28 | — | — | CN | disclosed |
| CN-1149215-C | Phenyl xanthine derivatives | GLAXO GORUP LTD (GB) | 2004-05-12 | — | — | CN | disclosed |
| US-20040034020-A1 | Methods of treating periodontal disease | DALUGE SUSAN MARY (US) | 2004-02-19 | — | — | US | disclosed |
| EP-1104422-B1 | PHENYL XANTHINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2004-02-18 | — | — | EP | disclosed |
| US-6608069-B1 | Treating AIDS-related diarrhea or infectious diarrhea, tissue damage or dermatitis associated with leukocyte infiltration into tissue, asthma, inflammatory bowel condition, eczema, or psoriasis | SMITHKLINE BEECHAM CORPORATION | 2003-08-19 | — | — | US | disclosed |
| US-20030032804-A1 | Methods of treating periodontal disease | SMITHKLINE BEECHAM CORPORATION | 2003-02-13 | — | — | US | disclosed |
| CN-1323309-A | Phenyl xanthine derivatives | GLAXO GROUP LTD (GB) | 2001-11-21 | — | — | CN | disclosed |
| EP-1104422-A1 | PHENYL XANTHINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009507-A1 | PHENYL YANTHINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034020-A1 | Methods of treating periodontal disease | MMP8, LPO, PTGES3 | ADORA2B 680/4885ADORA2A 660/4885PDE4A 45/4885 |
| US-20030032804-A1 | Methods of treating periodontal disease | HPGDS, SELP, ALPI | ADORA2B 439/4885ADORA2A 300/4885PDE4A 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.